Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway, which helps the immune system fight cancer. The main goals were to check safety, fi…

This phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…

This phase 2 trial tested a drug called KL-A167 in 153 adults with recurrent or metastatic nasopharyngeal carcinoma (a type of throat cancer). Participants received the drug by IV every two weeks. The main goal was to see how many patients' tumors shrank or disappeared. The study…

This early-stage study tested a new antibody drug (similar to cetuximab) in 18 people with advanced colorectal cancer that had stopped responding to standard treatments. The main goal was to check safety and how the drug moves through the body. Participants received one of two do…

This early-stage study tested a new drug called KL340399 in 6 people with advanced solid tumors that had not responded to standard treatments. The drug was injected directly into the tumor to see if it was safe and what dose might work best. The main goal was to find the highest …

This study tested whether a new drug called A140 works as well as the standard drug Erbitux for people with a certain type of advanced colorectal cancer (RAS wild-type). Both drugs were given together with chemotherapy. The trial involved 688 adults and measured how many patients…